Researcher
Peter Van Dam
- Research Expertise:Translational investigations in breat and cervical cancer Immune environment in inflammatory breast cancer and cervical cancer Effect of Denosumab on the immune environment of cervical cancer Quality control of cancer treatment Telemonitoring of sidde effects of cancer treatment Cognitive impairment after cancer treatment
- Keywords:T CYTOTOXIC LYMPHOCYTE, T HELPER LYMPHOCYTE, Medicine
- Disciplines:Cancer biology, Cancer diagnosis, Cancer therapy
- Research techniques:Immunohistochemical staining Flow cytometry RNA seq
- Users of research expertise:Other interested groups
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Feb 2014 → 31 Dec 2018
Projects
1 - 10 of 10
- Establishing patient-derived organoids to rationally design therapies for patients with inflammatory breast cancerFrom1 Nov 2023 → TodayFunding: Nonprofit institution or equivalents
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Development and validation of a novel rationally designed immunotherapeutic combination strategy built upon targeting RANK(L) for cervical cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Unveiling the drug repurposing versatility of denosumab in the battle against human cervical cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- RANK signaling and checkpoint inhibition.From15 Sep 2018 → 14 Sep 2021Funding: Nonprofit institution or equivalents
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Characterization of the stromal component in inflammatory breast cancer.From15 Jan 2016 → 14 Jan 2017Funding: Nonprofit institution or equivalents
Publications
71 - 80 of 108
- Neoadjuvant endocrine treatment in early breast cancer(2016)
Authors: Peter Van Dam, V. C. N. van Dam, Sevilay Altintas, Papadimitriou, Christian Rolfo, Xuan Bich Trinh
Pages: 333 - 342 - A cross-sectional, multicentre, epidemiological study on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical cancer in Belgium(2015)
Authors: Wiebren Tjalma, Xuan Bich Trinh, M. Rosenlund, Peter Van Dam, et al.
Pages: 101 - 108 - The effect of EUSOMA certification on quality of breast cancer care(2015)
Authors: Peter Van Dam, M. Tomatis, L. Marotti, J. Heil, R. Wilson, M. Rosselli del Turco, C. Mayr, A. Costa, M. Danei, A. Denk, et al.
Pages: 1423 - 1429 - The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab(2015)
Authors: K. Papadimitriou, Xuan Bich Trinh, Sevilay Altintas, Peter Van Dam, Manon Huizing, Wiebren Tjalma
Pages: 176 - 180 - Epidermal Growth Factor Receptor (EGFR) pathway biomarkers in the randomized phase III trial of erlotinib versus observation in ovarian cancer patients with no evidence of disease progression after first-line platinum-based chemotherapy(2015)
Authors: Evelyne Despierre, Ignace Vergote, Ryan Anderson, Peter Van Dam, et al.
Pages: 583 - 596 - Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease(2015)
Authors: Maurice P. H. M. Jansen, Leen Sas, Anieta M. Sieuwerts, Caroline Van Cauwenberghe, Diana Ramirez-Ardila, Maxime Look, Kirsten Ruigrok-Ritstier, Pascal Finetti, Francois Bertucci, Mieke M. Timmermans, et al.
Pages: 1218 - 1233 - Gene expression profiles of inflammatory breast cancer(2014)
Authors: F. Bertucci, N.T. Ueno, P. Finetti, Peter Vermeulen, Peter Van Dam, Luc Dirix, Steven Van Laere, et al.
Pages: 358 - 365 - Genomic profiling of inflammatory breast cancer(2014)
Authors: François Bertucci, Pascal Finetti, Peter Vermeulen, Peter Van Dam, Luc Dirix, Daniel Birnbaum, Patrice Viens, Steven Van Laere
Pages: 538 - 545 - Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel(2014)
Authors: C. Vulsteke, A.M. Pfeil, M. Schwenkglenks, Marc Peeters, Peter Van Dam, et al.
Pages: 557 - 570 - Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node(2014)
Authors: Anneleen Reynders, Olivier Brouckaert, Ann Smeets, Peter Van Dam, Cecile Colpaert, et al.
Pages: 453 - 459